Profile No. 6899 / San Francisco, California
Kareem Barghouti likes maps with missing streets. The useful question, in his telling, is what happens when a field can finally see routes that were present all along. In 2025, when he announced that he was joining Enveda as Entrepreneur-in-Residence, he described biology as a city drawn with only one percent of its roads. The image is vivid because it turns a difficult problem in chemistry into a familiar frustration: you know the destination may exist, but most of the directions are blank.
Barghouti has spent years working on ways to fill those blanks. First came VastBiome, the company he co-founded after a biodesign fellowship in Houston. It began by studying the enormous collection of genes and chemicals associated with microbes in the human body. VastBiome later became Pragma Bio, a name that shifted the emphasis from cataloging a microbial community to executing on its chemical instructions. The company used machine learning to prioritize promising relationships and synthetic biology to produce molecules worth testing.
Now the map is wider. Enveda gathers natural samples, reads complex mixtures with metabolomics, uses machine learning to connect chemical signals to structure and biological activity, and sends the resulting ideas through automated laboratories. Barghouti joined to lead an initiative that the company has not yet described in public. The details remain under wraps. The continuity is already visible: he is still interested in the part of nature that conventional catalogs miss.
“Imagine trying to navigate a city with only 1% of the streets drawn on the map.”Kareem Barghouti, announcing his move to Enveda
The first operating system
Before the laboratory, there was the sales floor. Barghouti studied biological sciences at UC Irvine, spent time studying physics at the University of Sussex and earned an MBA focused on healthcare at Duke’s Fuqua School of Business. His early work, however, ran through the startup and advertising worlds. He co-founded StingyCampus while in college, joined the social-media marketing company Wildfire Interactive and then went to Google, which acquired Wildfire in 2012.
At Google, he worked across sales, social media strategy, product marketing, data integrity and strategy and operations. A conference biography credits him with helping launch an online education product across Europe, overseeing systems that supported a large global advertising organization and contributing to work around commercializing ideas from Google X. The résumé looks far from a wet lab. The operating habits travel well: define the messy system, improve the data, build repeatable processes and help specialists work from the same picture.
The important difference was the clock. Software organizations can test a product change quickly. Drug discovery makes each claim pass through layers of experimental evidence. In a 2019 interview, Barghouti drew the contrast directly: technology companies tend to expect short returns, while biotechnology companies may wait a decade to commercialize an asset. His answer was a hybrid, not a shortcut. Computation could narrow the field. It could not grant a molecule credibility on its own.
A company born from conversations
In 2017, Barghouti left Google for the Texas Medical Center Innovation Institute’s Biodesign Fellowship. The program placed fellows close to medical professionals and unmet needs. Through those conversations, his team kept returning to the role of the microbiome and to a practical gap: researchers could observe associations among microbes, patient data and outcomes, but turning those signals into a drug program required a more useful unit than a bacterial name.
VastBiome formed in Houston in 2018, then moved to the Bay Area and participated in the Illumina Accelerator and Plug and Play. The young company also spent eight weeks in MassBio’s MassCONNECT program in Cambridge. Barghouti later described that stretch as unusually productive for the young company. The point was density. Within a few square miles, the team could find mentors in intellectual property, business development, drug discovery and financing. A network condensed months of cold approaches into repeated, informed conversations.
The company’s first map connected microbial genes, the enzymes encoded by those genes and the small molecules those enzymes might produce. Barghouti explained the commercial logic plainly. Pharmaceutical companies are accustomed to developing molecules, not entire microbial ecosystems. If biology suggested that a particular microbe mattered, the company wanted to identify the chemical reason, manufacture it and put it in front of a decisive assay.
Give every technology a specific job. Machine learning prioritizes. Synthetic biology produces. Experiments arbitrate. A platform becomes credible when the handoffs are clear.
The pragma in Pragma
The 2023 rebrand captured that progression. In programming, a pragma is a directive that helps turn code into executable action. Pragma Bio wanted to do something similar with genetic code: read microbial instructions, express selected pathways and recover their chemistry. The metaphor was unusually disciplined for a biotech name. It described a workflow, not merely an ambition.
Alongside the name, Pragma announced $10 million in new equity led by The Venture Collective, with Viking Global Investors, Merck Global Health Innovation Fund and CJ Investments participating. The announcement put total venture backing at $15 million. Barghouti’s comments focused on the relationship between nature and the body and on the patient work still ahead. His later comments about milestones were more revealing about his management style. Financing and partnerships mattered, he wrote, but people made or broke the startup.
That emphasis also appears in the colleagues around him. Pragma’s founding group included physician Peter McCaffrey and computational leader Ayin Vala. Natural-products researcher Mohamed Donia later joined as scientific co-founder and chief scientific officer. In 2024, the company added experienced advisers and an independent board member. Barghouti framed the appointments around humility, kindness and mission, the traits that determine whether impressive résumés can become a functioning team.
“Unlocking these molecules takes patience.”Kareem Barghouti on the pace of discovery
Patience did not mean waiting passively. Pragma built a discovery engine called Lattice, assembled genomic and biological datasets, produced candidate molecules and sought partnerships that could carry selected programs further. At a 2025 SynBioBeta conversation, Barghouti called the approach genome-informed biosynthesis. The phrase is technical. The idea is compact: let genetic information tell the laboratory which natural chemistry to make next.
The lunch interview
Earlier in 2025, Barghouti visited Enveda’s headquarters in Boulder. He later called the meeting his “lunch interview,” a casual catch-up with founder and CEO Viswa Colluru and several members of the leadership team. What stayed with him was a series of pairings: brilliance with humility, ambition with openness, competence with kindness, speed with rigor. The meal offered a cultural readout before the formal announcement did.
Enveda works on a related problem at a different breadth and scale. Its library begins with the chemistry of living systems across a wide natural collection. Its tools analyze mixtures that contain thousands of molecular signals, many without names in standard databases. The company then connects those signals with biological assays and uses structural prediction to propose what an unknown compound may be. Automation allows the loop to run repeatedly.
For Barghouti, the move expands a long-running thesis. Pragma searched for useful chemistry made by microbes associated with humans. Enveda searches a broader chemical universe made by living organisms. Both begin with the belief that natural systems contain more usable information than today’s molecular catalogs reveal. Both depend on computation, but neither ends at a prediction. Chemistry must be isolated or produced, tested and developed.
The timing mattered, too. Shortly before his arrival, Enveda had raised a $150 million Series D and reported a platform with more than a dozen development candidates. Barghouti described the company as filling in the missing streets of the chemical map and turning work that once took years into something that could happen much faster. He did not disclose the new initiative. He did say he believed it could become a substantial opportunity of its own.
What carries across the border
It is tempting to make Barghouti’s story a tidy migration from technology to biotechnology. The border is less clean. He studied biology before entering tech. He carried a healthcare focus through business school. His Google roles mixed human systems with data systems. The fellowship did not erase those years; it gave them a new object.
The useful through-line is translation. Sales translates a product into a reason to care. Operations translates a goal into repeatable work. Synthetic biology translates genetic instructions into physical chemistry. A founder translates among researchers, investors, partners and the public. Barghouti’s career has placed him repeatedly at those interfaces, close enough to several disciplines to keep the handoffs moving.
He also knows the danger of fashionable language. Back in 2019, he warned that loose claims around artificial intelligence and machine learning were making industry partners numb. The critique has aged well. In his version of an AI-enabled laboratory, the model is valuable because it chooses a better next experiment. The experiment still has the final vote.
That may be the clearest way to understand his new chapter. Enveda has built a larger mapmaking machine. Barghouti arrives with experience forming a company around a narrower section of the same unknown territory. His work now is to find a route through that machine that deserves its own destination. The streets are still incomplete. For him, that is the point.